Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response—a prospective open-label study

被引：0
|
作者：
Naoki Hashimoto
Atsuhito Toyomaki
Minoru Honda
Satoru Miyano
Nobuyuki Nitta
Hiroyuki Sawayama
Yasufumi Sugawara
Keiichi Uemura
Noriko Tsukamoto
Tsukasa Koyama
Ichiro Kusumi
机构：
[1] Hokkaido University Graduate School of Medicine,Department of Psychiatry
[2] Child and Adolescent Psychiatry,Department of Psychiatry
[3] Department of Psychiatry University of California,undefined
[4] Honda Memorial Hospital,undefined
[5] Teine Hospital,undefined
[6] Sapporo Hanazono Hospital,undefined
[7] San-ai Hospital,undefined
[8] Psychiatric Medical Center,undefined
[9] Sapporo City General Hospital,undefined
[10] Hakodate Watanabe Hospital,undefined
[11] Oyachi Hospital,undefined
来源：
Annals of General Psychiatry | / 14卷
关键词：
Schizophrenia; Quetiapine; Switching; Antipsychotic; Negative symptom; Cognitive impairment; Treatment resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study
    Apiquian, R
    Ulloa, E
    Fresan, A
    Loyzaga, C
    Nicolini, H
    Kapur, S
    SCHIZOPHRENIA RESEARCH, 2003, 59 (01) : 35 - 39
  • [32] Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study
    Filts, Yuriy
    Litman, Robert E.
    Martinez, Javier
    Anta, Lourdes
    Naber, Dieter
    Correll, Christoph U.
    SCHIZOPHRENIA RESEARCH, 2022, 239 : 83 - 91
  • [33] Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study
    Suresh Durgam
    William M. Greenberg
    Dayong Li
    Kaifeng Lu
    Istvan Laszlovszky
    Gyorgy Nemeth
    Raffaele Migliore
    Stephen Volk
    Psychopharmacology, 2017, 234 : 199 - 209
  • [34] Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study
    Correll, Christoph U.
    Cucchiaro, Josephine
    Silva, Robert
    Hsu, Jay
    Pikalov, Andrei
    Loebel, Antony
    CNS SPECTRUMS, 2016, 21 (05) : 393 - 402
  • [35] Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial
    Cutler, Andrew J.
    Kalali, Amir H.
    Mattingly, Greg W.
    Kunovac, Jelena
    Meng, Xiangyi
    CNS SPECTRUMS, 2013, 18 (01) : 43 - 54
  • [36] Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders
    Parellada, Eduard
    Kouniakis, Filippos
    Siurkute, Aldona
    Schreiner, Andreas
    Don, Liana
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2010, 25 (03) : 149 - 154
  • [37] Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study
    Saito, Takuya
    Hyodo, Yohei
    Sakaguchi, Reiko
    Nakamura, Hiroshi
    Ishigooka, Jun
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2022, 32 (01) : 24 - 35
  • [38] Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II
    Muenzer, Joseph
    Burton, Barbara K.
    Harmatz, Paul
    Gonzalez Gutierrez-Solana, Luis
    Ruiz-Garcia, Matilde
    Jones, Simon A.
    Guffon, Nathalie
    Inbar-Feigenberg, Michal
    Bratkovic, Drago
    Hale, Michael
    Wu, Yuna
    Yee, Karen S.
    Whiteman, David A. H.
    Alexanderian, David
    MOLECULAR GENETICS AND METABOLISM, 2022, 137 (1-2) : 92 - 103
  • [39] Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study
    Yagoda, Sergey
    Graham, Christine
    Simmons, Adam
    Arevalo, Christina
    Jiang, Ying
    McDonnell, David
    CNS SPECTRUMS, 2021, 26 (04) : 383 - 392
  • [40] Clinical efficacy of 0.1% cyclosporine A in dry eye patients with inadequate responses to 0.05% cyclosporine A: a switching, prospective, open-label, multicenter study
    Yoon, Sook Hyun
    Kim, Eun Chul
    You, In-Cheon
    Choi, Chul Young
    Kim, Jae Yong
    Song, Jong Suk
    Hyon, Joon Young
    Kim, Hong Kyun
    Seo, Kyoung Yul
    BMC OPHTHALMOLOGY, 2025, 25 (01)
12345